A decreased effect of incretins affects not only the secretion of insulin, but also other beneficial effects promoted via the GLP-1 receptor. This supports several modern proposed DM2 pharmacological therapies aimed at improving the effects of incretins.

In addition to the pancreas, adipocytes, liver, and intestines, the kidneys also play important roles in glycemic control. In the tubular reabsorption of glucose, renal gluconeogenesis also contributes significantly to glucose homeostasis. By , the first studies [ 16 ] on the role of the kidney in glycemic control were conducted in animals, and in the late s, studies on renal glucose metabolism were conducted in humans [ 17 — 20 ].

Several hormones are involved in regulating renal reabsorption of glucose: hyperinsulinemia blocks the secretion of renal glucose as it does in the liver [ 21 , 22 ].

However, epinephrine infusion increases the release of renal glucose [ 23 ], and this effect is not altered by glucagon [ 24 ]. Although there is not yet available data in humans, several studies suggest that cortisol and growth hormone may stimulate the release of renal glucose [ 25 , 26 ].

In individuals with DM, the Tm for glucose maximum capacity of renal tubular reabsorption of glucose is higher than in healthy individuals, thus worsening hyperglycemia. Because the kidneys play a role in glucose homeostasis, therapies have been developed to reduce tubular reabsorption of glucose, which is achieved by inhibition of the SGLT2 transporter.

Other therapies suppress both SGLT2 and SGLT1, with the aim of improving glycemia by increasing glycosuria. Unlike previous views regarding glycosuria, after the introduction anti-SGLT1 and -SGLT2 medications in the treatment of DM2, glycosuria has become a desired clinical sign.

Glucose homeostasis is extremely altered in patients with CKD, who are exposed to a high risk of both hyperglycemia and hypoglycemia.

Factors that are associated with an increased risk of hypoglycemia in CKD patients include decreased renal gluconeogenesis, deranged metabolic pathways including altered metabolism of medications and decreased insulin clearance.

On the other hand, decrease glucose filtration and excretion, and inflammation-induce insulin resistance are predisposing factors to hyperglycemic episodes Fig.

Appropriate glycaemic control tailored for diabetic patients is required to avoid haemodialysis-induced hypoglycaemia and other glycaemic disarrays [ 28 ]. As lack of glycemic control increases the rate of progression of renal failure, proper glycemic control in the early stages of CKD is crucial [ 29 ].

The United Kingdom Prospective Diabetes Study UKPDS provided the first evidence that intensive glycemic control, determined by a more aggressive therapy combined with monitoring and more frequent medical follow-up, could reduce the long-term complications caused by DM2 [ 30 ]. Although hyperglycemia is the biochemical marker of DM, hemoglobin A1c HbA1c has slowly become the cornerstone for the diagnosis and monitoring of DM since its introduction into routine clinical practice in [ 31 ].

There are confounding factors in the measurement of HbA1c, among which we have previously reported the difference in intracellular-extracellular glucose homeostasis, the survival time of red blood cells hemolytic anemia , and non-glycemic genetic determinants of hemoglobin glycation.

For this reason, the use of HbA1c as the only criterion for the diagnosis of DM in non-Caucasian individuals can lead to misclassification. In addition to its recent role as a diagnostic marker, HbA1c is also used to evaluate the degree of metabolic control in diabetics and to predict the risk of vascular complications [ 32 , 33 ].

There is conflicting evidence on the role of HbA1c in reflecting long-term glycemic control in patients with CKD.

Moreover, the association between glycemic control and outcomes may be different in patients with or without CKD. Uremia causes a unique internal environment, which creates the need to assess each case in a personalized manner. Therefore, markers for monitoring glycemic control, specifically in individuals with CKD, need to be evaluated [ 34 ].

Glucose monitoring for the prevention of acute and chronic complications is critical in the management of DM. Therefore, we will discuss the main markers for glycemic control and their limitations in patients with CKD.

In a perfect scenario, glucose analysis should minimize total analytical error, and methods should be without measurable bias [ 35 ].

Enzymatic methods for glucose analysis are well standardized. A survey conducted by the College of American Pathologists CAP reveals that hexokinase or glucose oxidase is used in nearly all analyses performed in the U.

few laboratories use glucose dehydrogenase. Glucose is stable for 8 h in samples collected with an antiglycolytic agent. In plasma, serum, and other liquids already separated from cells, the level of glucose is stable for 3 days at 2—8 °C if there is no bacterial contamination [ 36 ].

The collection should be preceded by a fasting period of 8—12 h, with water intake. Physical activity and a habitual diet are recommended the day before the examination as well as a standard diet of g carbohydrates [ 36 ].

SM is a valuable resource for both the patient and the doctor, as it is undoubtedly among the markers for glycemic control that provide the greatest amount of information about daily nutrition and the resultant glycemic responses.

Pimazzoni et al. established several criteria that must be followed in order to produce favorable results, optimizing the use of SM [ 37 ]:. The patient should be instructed regarding the proper use and benefits provided by the correct SM practice. The patient should follow a continued practice of DM education, not only in the initial discovery of the disease but also as the disease evolves.

There is no frequency of tests that can be recommended to all patients. On the contrary, this frequency should be individualized and adapted to the clinical conditions of each patient. The SM results should be effectively used by the physician and other health professionals, to promote constant adjustments in the therapeutic conduct and supplementary guidance of nursing, nutrition, psychology, and physical education.

SM does not interfere with monitoring in diabetic patients with CKD. Its limitations include the need for training and economic access to tapes.

However, there is no doubt that establishing a pattern of glycemic variation is fundamental. The importance of glycemic variability as an isolated factor for cardiovascular risk is well established [ 38 ].

Another important parameter regarding SM is the potential to download the information on specific software, generating accompanying graphs that facilitate understanding and decision-making. Glycation is a nonenzymatic reaction of glucose binding to a protein, in this case, to hemoglobin, yielding glycated hemoglobin, or HbA1c.

In keeping with this notion, the term glycosylated hemoglobin is incorrect. This process is concentration- and time-dependent. In practical terms, this means that the greater the concentration of glucose available, the higher the concentration of HbA1c.

In contrast, over time, there is a lower the binding of glucose to hemoglobin [ 39 ]. In contrast to plasma glucose, HbA1c represents nonenzymatic glycation, which depends on the concentration of glucose in the intra-erythrocytic compartment.

Although several studies found a good positive correlation between the concentrations of HbA1c and glucose in diabetic patients with and without CKD, the variable relationship between HbA1c and estimated average glucose remains a potential source of concern [ 40 ].

Ninety-four percent of HbA undergoes no action induced by any sugars and is called HbA0. In turn, HbA1c is divided into subtypes in accordance with the type of sugar that produces glycation. Twenty percent of HbA1c is influenced by fructose-1,6-diphosphate and glucosephosphate, forming HbA1a and HbA1b.

The following methods are approved by the National Glycohemoglobin Standardization Program NGSP : high performance liquid chromatography HPLC—a method that was applied in the diabetes control and complications trial DCCT , boronic acid affinity chromatography, enzymatic, immunoassay, and capillary electrophoresis.

Since different methods quantify different ratios of glycated hemoglobin, the results are different. However, an excellent correlation was observed in a sample without hemoglobin variants or the presence of interfering factors.

Through NGSP, the values of glycated hemoglobin can be expressed to provide equivalent results of the glycemic status of the patient, regardless of the method used, thus the same criteria can be widely applied. NGSP standardized these methods for the results to be comparable to those obtained by DCCT, in which the relationship between the average levels of blood glucose and the risk for vascular complications was established.

org [ 41 ]. Interference in the dosage of HbA1c might occur and depends on the method used: factors increasing HbA1c measurements include renal impairment increased urea binds to hemoglobin, producing carbamylated hemoglobin that interferes with HbA1c measurement ; use of acetylsalicylic acid binds to hemoglobin, producing acetylated hemoglobin, which interferes with HbA1c measurement; usually, this occurs with high doses of acetylsalicylic acid ; hypertriglyceridemia; and hyperbilirubinemia.

Finally, factors decreasing HbA1c measurements include hemoglobin glycation inhibition factors e. Interference might occur with the dosage of HbA1c, depending on the method: factors increasing HbA1c measurements include polycythemia, anemia due to iron deficiency, folic acid, or vitamin B12; chronic alcoholism; and opiates.

Factors decreasing HbA1c measurements include conditions that shorten the half-life of red blood cells e. Fasting is not necessary for the collection of the material. Whole blood collected using EDTA as anticoagulant. The blood can be stored in a refrigerator for a week.

Heparinized samples should be assayed in a maximum of 48 h [ 41 ]. In addition to glucose, other factors might also influence HbA1c: this is the main reason for which the dosage of HbA1c is questioned in patients with CKD.

Among these influences, we highlight a few. First, the formation of HbA1c is dependent on the interaction intensity and duration between the concentrations of glucose and blood erythrocytes. On average, erythrocytes survive days in men and days in women.

At a certain point, a blood sample contains erythrocytes of different ages, mainly younger elements and with different degrees of exposure to hyperglycemia [ 40 ]. HbA1c is a measure for the mean level of blood glucose in the past 90 days.

An unexplained discrepancy between HbA1c and other measurements of glycemic control can be partly due to the different life span of erythrocytes. Decreased erythropoiesis, caused by iron or vitamin B12 deficiency or aplastic anemia, leads to an increased number of aged red blood cells and a subsequent progressive increase of HbA1c, unrelated to glycemic control [ 43 ].

Conversely, a decrease in HbA1c is observed after the administration of erythropoietin, iron, and vitamin B12, and in cases of hemolytic anemia. Due to a reduction in the survival of red blood cells, younger erythrocytes have less time to be exposed to a glycemic environment and therefore undergo less glycation [ 44 ] Hemoglobinopathies, of which the most common example is sickle cell anemia and thalassemia, can lead to problems in the interpretation of HbA1c.

In case of these changes, in addition to the normal HbA0 glycation to form HbA1c, other glycation products derived from HbC African populations , HbD indigenous populations , HbE Asian populations , or HbS sickle cell anemia could be formed [ 43 ]. In the third National Health and Nutrition Examination Survey, alcohol consumption was associated with low levels of HbA1c in adults with DM.

These findings were confirmed in a large follow-up study of 38, adult patients with type 1 or 2 DM. An increase in alcohol consumption predicts lower HbA1c values.

Also, the intra-erythrocytes pH can interfere HbA1c. In patients with chronic renal failure, lipid peroxidation of Hb can increase hemoglobin glycation.

Chronic ingestion of aspirin and high doses of antioxidants e. It is unclear whether these phenomena could change clinical practice [ 45 ]. In addition to the changes described above, it is important to highlight that new methods detect differently the presence of hemoglobinopathies, and the presence of carbamylated hemoglobin can interfere with the dosage.

HbA1c measured by HPLC detects the carbamylated fraction differently than does immunoturbidimetry, which does not identify this fraction; consequently, patients with renal failure present higher levels of HbA1c when measured using HPLC [ 44 ]. The dosage of glycated albumin GA is gaining interest as a potential marker of glycemic control.

GA is a ketoamine formed by the non-enzymatic oxidation of albumin by glucose. As the half-life of albumin is of approximately 15 days, GA is used as a short-term measurement of glycemic control, that is, 2—3 weeks, and as such, it might act as an intermediate time index of glycemic control [ 44 ].

Several methods can be used for the measurement of GA, including affinity chromatography, ion-exchange chromatography, HPLC, immunoassay techniques, capillary electrophoresis, and other electrophoretic and enzymatic assays. It is not influenced by sex, red blood cell life span, or erythropoietin therapy; however, for serum albumin concentration, the results are conflicting [ 46 ].

However, the results can be influenced by age, nutritional status, albuminuria, cirrhosis, thyroid dysfunction, and smoking. GA is inversely influenced by body mass index, body fat mass, and visceral adipose tissue [ 46 ].

Fructosamine is the generic name given to all glycated proteins, of which albumin is the major plasma fraction, after hemoglobin. Although the dosage of fructosamine can be automated, thus making it cheaper and faster than HbA1c measurement, there is no consensus on its clinical utility [ 47 ].

The level of fructosamine correlates better with the average glucose levels over the previous 10—14 days. Moreover, fructosamine is influenced by the concentration of bilirubin and substances with low molecular weight, such as urea and uric acid.

GF is not modified by changes in the metabolism of hemoglobin. However, it is affected by disturbances in protein turnover. The reference values depend on age, sex, sample population, and test method applied [ 48 ]. Unfortunately, the data show conflicting results concerning the correlation between fructosamine and glucose concentrations in patients with CKD.

The values may be influenced by nephrotic syndrome, thyroid diseases, administration of glucocorticoids, liver cirrhosis, and jaundice [ 48 ]. The physiological function and metabolism of 1,5-AG are not well defined.

The levels of 1,5-AG in blood are altered less than 24 h after hyperglycemic episodes, and the repetition of these episodes dramatically decreases its concentration.

The values of 1,5-AG reflect hyperglycemia over a period of approximately 1 week. In addition to the glycosuria threshold, the measurement of 1,5-AG could play an adjuvant role in the control of DM, especially as a short-term single marker for hyperglycemia excursions [ 50 ].

The relationship between HbA1c and glucose is more complex in more advanced stages of CKD due to the great variability in hemoglobin, nutritional status, and inflammation. Moreover, these underlying comorbidities may also hinder the prognostic value of HbA1c [ 44 ].

Figure 2 shows the correlation between each marker and the time of hyperglycemia that each indicates. However, these guidelines refer mainly to the initial stages of CKD. A recent meta-analysis, investigating the relationship between HbA1c and risk of death in diabetic hemodialysis patients, showed that the level of HbA1c remains a useful clinical tool for the prediction of the mortality risk [ 52 ].

Although glycated albumin presents advantages in patients with CKD, several authors argue that CKD is characterized by the disruption of albumin homeostasis and that the threshold of serum albumin for which the risk of death increases varies according to the dialysis modality [ 53 ].

In the presence of hypoalbuminemia, plasma protein glycation is increased. However, glycated albumin seems to reflect the percentage of albumin that is glycated, regardless of the concentration of total serum albumin, although more studies on a large scale with dialysis patients would be required to confirm this observation [ 54 ].

Glycated albumin seems to be a better marker to reflect the accuracy of glycemic control when compared to HbA1c in patients with DKD. However, due to limited data, the absence of studies on the results of interventions based on glycated albumin and its expensive and laborious methodology, indicate that it might be premature to abandon HbA1c in favor of glycated albumin [ 55 ].

Thus, our recommendation is that diabetic patients with CKD would be monitored in the best possible way, in the attempt to prevent the progression of the disease and an increase in complications. Therefore, we suggest monitoring HbA1c every 3 months, which can be associated with home SM when possible.

Other exams such as glycated fructosamine, glycated albumin, and 1,5-AG could be used as additional tools, rather than replacing HbA1c.

Glycemic control is fundamental in the prevention and progression of complications associated with DM [ 56 , 57 ]. However, in recent years, the associations focused on the treatment of DM have systematically reviewed the optimal values of glycemia and HbA1c goals for diabetic patients, with the aim to define individualized objectives to prevent the onset of chronic complications, aiming also to reduce the occurrence of hypoglycemia.

After this study, associations such as ADA began to recommend individualized HbA1c goals for patients with a history of severe hypoglycemia, limited life expectancy, patients with microvascular or macrovascular complications in advanced stages, and patients with multiple comorbidities.

Specifically in relation to DKD, classical studies have also previously demonstrated that improved glycemic control is associated with a reduced incidence of albuminuria in both type 1 and type 2 DM [ 56 , 57 ].

Even in secondary prevention, i. The ADVANCE action in diabetes and vascular disease trial showed that intensive control was able to reduce albuminuria, nephropathy, and the need for hemodialysis [ 63 ]. Similarly, the ACCORD trial showed a significant reduction in albuminuria although not in advanced renal disease in the group treated with an intensive therapy for glycemic control [ 60 ].

However, despite evidence correlating the optimization of glycemic control to the benefits observed in the evolution of DKD, glycemic and HbA1c objectives are very difficult to define and achieve in this population. The complexity of glycemic control in this group of patients is explained not only by the metabolic alterations associated with DKD, but also the specificity and greater difficulty in the use of hypoglycemic drugs, difficulty in monitoring glycemic levels, behavioral addictions related to years of DM and a fear of hypoglycemia, as well as sociocultural and economic factors.

DKD progresses with several metabolic changes, which occur concomitantly with the progressive decline in glomerular filtration rate GFR. Using the euglycemic insulin clamp, DeFronzo et al. showed that the glucose used by peripheral tissues in response to insulin is reduced in uremia [ 64 ].

The increased insulin resistance is related to the accumulation of uremic toxins, markers of chronic inflammation, increased visceral fat, oxidative stress, and vitamin D deficiency. Progression to uremia is associated with decreased insulin sensitivity of peripheral tissues, increased hepatic gluconeogenesis, decreased glucose uptake by skeletal muscle cells, and deficiency of intracellular glycogen synthesis and subsequent hyperglycemia [ 65 ].

On the other hand, the risk of hypoglycemia is a constant concern, since this is increased in diabetic patients with CKD.

The pathogenesis of hypoglycemia in these patients is related to changes in glucose metabolism, decreased insulin degradation, and changes in the metabolism of hypoglycemic agents.

With a progressive reduction in GFR, we observed a decrease in the clearance of oral hypoglycemic agents, and sometimes, a longer time of action of these drugs and their active metabolites. Similarly, insulin metabolism is also altered, since part of its metabolization and excretion is carried out by the renal system [ 66 — 68 ].

A restricted diet, either by prescription or even due to uremia, reduces hepatic gluconeogenesis, thus contributing to the occurrence of hypoglycemic episodes observed at higher frequency in this population [ 69 , 70 ].

Therefore, since CKD is a condition that increases predisposition to hyperglycemic and hypoglycemic peaks, the choice of drug treatment for these patients should be carefully considered [ 71 — 73 ].

Insulin is the therapy of choice for the treatment of diabetic patients with advanced CKD, and for insulinization to occur properly. Adherence and understanding of patients are of utmost importance. In phases IV and V of CKD, almost all patients with DKD in which DM is the central determinant in the etiology of DKD need insulin.

Patients with advanced CKD in which DM is another comorbidity, rather than the etiology of CKD, require insulin less frequently. Therefore, it is important that attending physicians have a broad knowledge of the arsenal of oral hypoglycemic agents that are currently available, in order to avoid the use of insulin when possible and the inappropriate and dangerous use of oral hypoglycemic agents.

In any case, most patients with advanced CKD need to use insulin for the safe and effective control of DM. However, for this to be achieved, a number of points should be discussed with the patient and the family:. Conduction of pre- and postprandial capillary blood glucose tests, also conducted at dawn, facilitating dose adjustment.

These guidelines require a commitment not only from the patients and their families, but also from a multidisciplinary team to make certain that the procedures are fulfilled. It is known that many diabetic patients who evolve towards a progressive loss of renal function have a personal history of poor adherence to the treatment, either due to inherent factors of the patient or the difficulty of the health system in dealing with a complex framework, thus demanding specific care.

We also noticed that many patients with advanced stage kidney disease often have comorbidities that further hamper their adherence to the treatment. Patients with diabetic retinopathy DR or those who have undergone amputation require the support of their families for periodic consultations, drug administration, and completion of capillary blood glucose monitoring tests.

The awareness and motivation of the patients and their families to complete the proposed treatment strategies in order to achieve the necessary goals for proper metabolic control should always be reviewed and emphasized by the multidisciplinary team.

It is important that the entire team pays attention in identifying the problems that can range from understanding the subject, to access to information and inadequate use of insulin. These habits are particularly common in patients with a history of poor glycemic control caused by self-medication for many years or by extreme fear of hypoglycemic episodes that led to the use of lower doses of insulin most often not disclosed to the medical team.

A condition often observed in populations of lower socioeconomic conditions is concurrent very high glycated hemoglobin levels and frequent episodes of hypoglycemia. Therefore, the best option is to provide DM re-education, review dietary patterns, and ensure fractionation of insulin dosage.

Often, however, the medical team responds inadequately, and insists on increasing the insulin dose, which the patient reduces without reporting the decrease because of fear of worsening hypoglycemia.

This creates a complete dissociation between the healthcare team and patient, with mutual loss of trust and overall inefficacy of the treatment. If this occurs, the process of re-education becomes even more important, since in addition to directly approaching patients and their families, it becomes necessary to work on concepts, insecurities, and prescription patterns of the attending medical team.

However, as already mentioned, the importance of individualization of HbA1c goals has already recognized by the ADA [ 59 ]. Blood pressure control is fundamental in the management of kidney disease progression. In general, diabetic patients with lower blood pressure levels and renal disease tend to experience slower progression of the pathology compared to hypertensive patients with the same condition [ 77 ].

Non-pharmacological measures dietary changes and increased physical activity have an impact on blood pressure control and should be encouraged. Drugs inhibiting the renin-angiotensin system through its specific renoprotective effect, regardless of the reduction in systemic blood pressure, have a well-established role in diminishing albuminuria and DKD progression [ 78 ].

Studies comparing the effect of angiotensin-converting enzyme ACE inhibitors and angiotensin II receptor blockers ARBs reported similar effectiveness. Therefore, ACE inhibitors or ARBs are recommended in patients with CKD, regardless of their ethnicity, as first-line treatment or in combination with another antihypertensive drugs [ 79 ].

Dose adjustment for these agents should be gradual, with periodic assessment of renal function and potassium levels, since there is a risk for creatinine level elevation and hyperkalemia. Greater attention must be paid to monitoring elderly patients and individuals with advanced stage CKD.

In December , the 8th Joint National Committee of Hypertension discussed new strategies for blood pressure control, and it was recommendation that ACE inhibitors and ARBs should not be used in the same patient simultaneously due to the following concerning findings: first, the VA-NEPHRON D trial [ 80 ] was prematurely terminated because of concerns about a high prevalence of hypotension, hyperkalemia and acute kidney injury with dual renin-angiotensin system RAS therapy.

The treatment effect was, however, not still appreciable at 2. These data strongly suggest that also in the VA NEPHRON-D trial, end-stage renal disease events could have been significantly reduced over the initially scheduled 5-year study period. Consistently, the results of a recent meta-analysis showing that dual RAS blockade with ACE inhibition and ARB is the most effective strategy to prevent end-stage renal disease in patients with diabetes and kidney disease [ 81 ].

The development of objectives to achieve adequate blood pressure levels to reduce cardiovascular events and progression of kidney disease has been the goal of recent studies. The frequency of macroalbuminuria at the final visit was significantly lower in the intensive-therapy group than in the standard-therapy group, and there was no between-group difference in the frequency of end-stage renal disease or the need for dialysis.

Optimal blood pressure values have not been established. However, in , the ADA aligned its recommendations with hypertension guidelines, recommending the maintenance of a systolic blood pressure lower than mmHg and diastolic pressure below 90 mmHg as goals for the treatment of hypertensive diabetic patients [ 59 ].

Additional positive phase 2 clinical studies with drugs that have hemodynamic actions such as endothelin antagonists and mineralocorticoid receptor antagonists have led to larger phase 3 trials with atrasentan and finerenone, respectively, in order to address if these drugs indeed delay the development of end-stage renal disease [ 83 ].

Positive findings with respect to new glucose-lowering agents such as sodium-dependent glucose transporter 2 inhibitors may lead to a change in the way we treat diabetic individuals with or at risk of DKD. A number of other pathways are currently under active preclinical investigation and hopefully over the next decade will lead to promising drug candidates for subsequent clinical trials [ 83 ].

DM and CKD present a significant correlation with increased cardiovascular risk. The risk of events in patients with CKD is considered equivalent to that in patients with a history of coronary disease. Therefore, the combination of these two conditions classifies the patient with DKD as presenting a very high risk for a cardiovascular event.

Considering the exacerbated cardiovascular risk of these patients, kidney disease: improving global outcomes KDIGO does not recommend the use of routine low-density lipoprotein LDL cholesterol level testing to identify patients to be treated or the objectives of the treatment [ 84 ].

The current recommendation indicates the use of statins as drugs of choice since their efficacy in primary and secondary prevention of cardiovascular events has been proven, regardless of LDL levels [ 76 , 84 ].

However, the appropriate dosage remains controversial. This recommendation is based on the reduction of renal excretions valid for some statins and associated comorbidities. However, no studies have shown an increase in adverse events using high doses of statins, and the prescription information of atorvastatin states that there is no need for a dose adjustment in patients with CKD [ 85 ].

On the other hand, it is known that patients with CKD have an increased risk of muscle damage with the use of statins, therefore this group of patients should be monitored more carefully. Results of studies on the use of statins in individuals undergoing dialysis, in whom the cardiovascular risk is very high, have been disappointing.

Despite the high risk, the cardioprotective effect of statins seems to be less efficient than in other populations. Therefore, the systematic use of statins in dialysis patients is not currently recommended, due to the lack of observed benefits of this intervention in different studies.

However, diabetic patients on dialysis continue to receive this drug due to the extrapolation of the proven benefits of statins in the diabetic population in general.

DR diabetic retinopathy is a microvascular complication that can occur in type 1 and type 2 diabetic patients, and its prevalence is closely related to the duration of the disease. DR is the most frequent cause of blindness in adults aged 20—74 years.

The pathogenesis of DR is directly linked to chronic hyperglycemia, and diabetic kidney disease is an important factor for an increased risk of DR incidence. DR and diabetic nephropathy are the two most common microvascular complications in patients with DM; however, whether these complications are only related or directly affect each other, or if their progression necessarily occurs simultaneously, is unclear [ 88 ].

Diabetic patients can eventually develop proteinuria, without the presence of DR, or might proliferative DR without the presence of albuminuria. Klein et al. Proliferative retinopathy is already considered a predictive factor for macroalbuminuria in type 1 diabetic patients.

Some authors consider both microalbuminuria and DR to be predictor factors for the progressive loss of kidney function [ 90 ]. ADA recommends periodic fundus examinations for retinopathy to be treated in a timely manner, before it progresses to irreversible vision loss.

Examinations should be conducted at least annually and can be conducted more frequently depending on the degree of retinopathy [ 58 ]. Diabetic autonomic neuropathy is a severe complication of DM and is associated with increased morbidity and mortality and decreased quality of life of the patients.

Diabetic autonomic neuropathy can affect different systems. Diabetic cardiovascular autonomic neuropathy DCAN can manifest clinically as resting tachycardia, severe orthostatic hypotension, syncope, ischemia and asymptomatic myocardial infarction, systolic and diastolic left ventricular dysfunction, increased risk for CKD, stroke, hyporesponsiveness to hypoglycemia, and sudden cardiac death [ 91 ].

The association between DCAN and kidney disease is also well established and corroborates with the increase in mortality rates in diabetic patients with CKD.

Ewing et al. A recent study showed that DCAN presents an important relationship with CKD, albuminuria, and decline in renal function in patients with DM2 [ 95 ].

Treatment of dysautonomic manifestations is essentially symptomatic. Special attention should be given to the intensification of glycemic control, with monitoring of hypoglycemia and changes in lifestyle, including diet and exercise [ 96 ].

Regarding drug treatment, fludrocortisone and the α 1-adrenergic agonist midodrine are considered the drugs of choice in the treatment of DCAN. Erythropoietin is also considered a possible adjunctive drug to increase blood pressure through an increase in the number of erythrocytes and central blood volume, correction of anemia in patients with severe dysautonomia, and neurohumoral effects on wall and vascular tone.

Almost half of the patients with DM develop some degree of bladder dysfunction. This prevalence may be even higher in populations with advanced CKD who have DM for a long time, or it may be due to the uremic syndrome per se.

Bladder dysfunction might result in varying degrees of impairment, ranging from a mild decrease in bladder sensitivity, reduced emptying perception, and alteration in contractility, to situations where there is an increase in bladder capacity, urinary retention, increased frequency of urinary tract infections, lithiasis, and renal failure [ 97 ].

In diabetic patients with CKD, the most common causes of erectile dysfunction are organic and are due to vascular disease and neuropathy. The initial treatment approach for erectile dysfunction in diabetic patients should be glycemic and metabolic control of other associated complications.

Specific measures of treatment include drug therapy group of phosphodiesterase inhibitors: sildenafil, vardenafil, and tadalafil. Intracavernous or intraurethral drugs papaverine, phentolamine, and prostaglandins are also used, as well as penile prostheses and vacuum devices [ 96 , 99 ].

However, the use of these drugs requires a more careful evaluation of CKD because of an increased risk of arrhythmias and heart failure. As diabetic patients experience progressive loss of renal function, nutritional issues become more complex.

On one hand, in addition to the existing limitations associated with DM, specific restrictions are needed for patients with CKD, including restriction of protein, phosphorus, and potassium. On the other hand, patients with worsening uremic syndrome have a higher risk of protein-calorie malnutrition that needs to be identified and addressed by the medical team.

Thus, nutritional monitoring is of utmost importance in this patient population. Standardized protocols should be avoided, and individualized care and monitoring of patients should be implemented.

Initially, patients should be evaluated based on their standard intake and clinical laboratory results. Then, a nutritional counseling plan should be designed based on nutritional guidelines that aid in the development of appropriate diets for patients, always considering individual needs. For the population of diabetic patients with CKD in the non-dialytic phase, the composition of macronutrients in the nutritional plan is described in Table 1.

For patients with DKD, the ADA recommends a normoproteic diet 0. Protein restriction aims to act simultaneously as a renoprotective measure, reducing both proteinuria and generation of protein catabolic waste. It is important to highlight that provision of a diet low in protein should ensure an adequate energy supply.

Regarding glycemic control, the recommended amount of carbohydrates follows the recommendations for the general population Table 1.

The quantity and quality of carbohydrates in the diet and its effects on glycemic responses are well established. The use of sweeteners, although indicated, is not essential for the treatment of DM.

The use of sweeteners can provide beneficial effects, such as weight loss in overweight or obese patients, due to their low caloric value, thus also reducing insulin.

In addition, adequate intake of food rich in complex carbohydrates dietary fibers should be encouraged, since this consumption is associated with glycemic control, satiety, and lipid absorption, thus also contributing to weight control. Although consumption of dietary fibers, especially in the soluble fraction, should be encouraged, it is important to highlight that, in general, foods rich in this nutrient fruits, vegetables, and legumes—are also sources of potassium, a mineral for which intake should be controlled in patients with CKD.

Main sources of dietary fibers with low potassium levels are fruits such as pineapple, apple, pear and strawberry, and vegetables such as carrot, watercress, lettuce, escarole, cucumber and cabbage.

One method that can be used to control blood glucose in these patients is carbohydrate counting, in which grams of this macronutrient obtained from meals are recorded throughout the day. This method is efficient in food control and the use of insulin, and its orientation should be individualized.

The recommendations for lipid consumption in diabetic patients are the same as those for individuals with cardiovascular diseases Table 1 , since both patients are at high risk for cardiovascular events.

In an interesting study conducted by Cardenas et al. In the same study, it was found that patients with worsening symptoms consumed higher amounts of saturated fatty acids during the 7-year follow-up. Considering that arterial hypertension is a factor for the progression of diabetic nephropathy, blood pressure control is essential for the treatment of the disease.

In a study conducted by Houlihan et al. Control of blood glucose levels in diabetic patients with CKD in different stages is not adequately standardized. Due to the increased risk of hypoglycemia [ ] in these patients, insulin has been considered the safest antidiabetic agent.

However, new non-insulin antidiabetic agents proved to be safe and effective. New revisions and guidelines are being published to guide the glycemic control of patients with CKD [ 70 , , ]. Regarding the therapeutic goals, the benefits of strict control of blood glucose levels in recently diagnosed diabetic patients [ ] is not observed in diabetic patients with the disease for a long time and who have already developed cardiovascular complications [ 60 , 63 , ], typical of diabetic patients with CKD.

This is explained by the increased risk of hypoglycemia episodes associated with a more intensive management of DM and the fact that these patients are more susceptible to the deleterious effects of hypoglycemia, such as activation of the sympathetic nervous system. However, there are benefits of controlling blood glucose levels in diabetic patients with CKD in terms of reducing mortality rates [ ], inhibiting progression of CKD [ , ], and diminishing albuminuria [ ].

Nevertheless, the therapeutic goals should be individualized and it should be considered that HbA1c overestimates glycemic control in patients with CKD [ ].

Below we discuss several aspects related to CDK of noninsulin antidiabetic agents that are not available in our environment. Metformin acts primarily in the liver, decreasing the production of hepatic glucose. Therefore, it is associated with low risk of hypoglycemia. This drug has been used for several years and has proven to reduce cardiovascular events [ ] and contribute to mild weight reduction.

Thus, it is considered the first choice drug in the treatment of DM2 [ ]. This drug is excreted by the kidney and therefore, in patients with CKD, it may accumulate and increase the risk of lactic acidosis, which is a side effect of this drug.

The relationship between metformin accumulation and lactic acidosis is not well documented [ ]. Factors such as acidosis, hypoxia, infection, and dehydration are also associated with the advent of lactic acidosis in patients receiving metformin, and in these situations, the drug should be suspended temporarily.

Sulfonylureas act in pancreatic β-cells, releasing insulin. The effectiveness of the class depends on the stores of β-cells, which decreases with the length of the DM. The action of these drugs is independent of glucose levels. Therefore, hypoglycemic episodes are more severe and frequent with the use of sulfonylureas [ ].

In patients with CKD, the use of short-acting sulfonylureas metabolized in the liver, including glipizide, gliclazide, and glimepiride, is recommended.

Sulfonylureas can bind to proteins and are not eliminated by dialysis. Similarly, glinides, such as repaglinide and nateglinide, act in pancreatic β-cells, releasing insulin. However, these drugs have a shorter half-life and cause less hypoglycemia [ ]. Glinides are metabolized predominantly in the liver.

Glitazones, such as pioglitazone and rosiglitazone, increase insulin sensitivity in muscle and adipose tissues by acting on PPAR-ɣ receptors. These drugs are metabolized in the liver, do not accumulate in CKD, and do not cause hypoglycemia, even in patients undergoing dialysis.

They are associated with water and salt retention, which limits the use of this class in CKD. It has been shown that the use of rosiglitazone is associated with an increased risk of myocardial infarction [ ] and increased cardiovascular mortality in patients undergoing hemodialysis [ ].

Therefore, pioglitazone has been used more frequently. Glitazones are also associated with a higher risk of fractures and bladder cancer. Despite the low risk of hypoglycemia, this class of drugs should be avoided in patients with CKD.

Acarbose acts in the gut by inhibiting alpha-glucosidase, the enzyme responsible for digesting carbohydrates. It does not cause hypoglycemia. Its main side effect is flatulence. In CKD, its use should be avoided, since it accumulates and can cause hepatotoxicity [ ].

In the glomeruli, about g of glucose per day is filtered, and nearly all is reabsorbed in the S1 segment of the proximal tubule by sodium-glucose cotransporters.

Of these, type 2 cotransporters are the most important [ ]. Drugs that inhibit this transporter have been developed, such as dapagliflozin, canagliflozin, and empagliflozin. These drugs block reabsorption of glucose and sodium in the proximal tubule, contributing to improved glycemic control, with no risk of hypoglycemia, as well as hypertension control, due to increased natriuresis.

The use of these drugs is associated with a higher incidence of genital infection. Recent data suggests cardiovascular benefits of this class, opening opportunities for a broader application of SGLT-inhibitors [ ].

GLP-1 is an incretin secreted in the gastrointestinal tract in response to food intake. It acts on pancreatic β-cells, releasing insulin, and in pancreatic α-cells, inhibiting the secretion of glucagon in a glucose-dependent manner; therefore, GLP-1 controls blood glucose with a lower risk of hypoglycemia.

Moreover, it slows gastric emptying and decreases appetite through a central mechanism, thus contributing to weight loss. GLP-1 receptor agonists, such as exenatide and liraglutide, are peptides with a structure similar to endogenous GLP However, these drugs are resistant to enzyme dipeptidyl peptidase-4 catabolism.

The route of administration is subcutaneous. Since they are peptides, they are filtered in the glomeruli and degraded in the proximal tubules, similar to the process associated with insulin.

There is little knowledge regarding this class of antidiabetic drugs in CKD, although gastrointestinal effects are exacerbated in patients with CKD, including nausea, vomiting, and diarrhea.

Moreover, there have been reported cases of acute renal injury with the use of exenatide in patients with CKD [ ]. DPP-4 is an enzyme that degrades GLP-1 and GIP incretins.

Therefore, DPP-4 inhibitors increase the concentrations of GLP-1 and GIP, which, as mentioned above, act in pancreatic β-cells by releasing insulin, and in pancreatic α-cells, inhibiting the secretion of glucagon in a glucose-dependent manner, thus controlling blood glucose with no risk of hypoglycemia.

The greatest effect of DPP-4 inhibitors is in the postprandial period, when the levels of glucose are elevated.

DPP-4 inhibitors are also known as gliptins. Four gliptins are available: vildagliptin, sitagliptin, saxagliptin, and linagliptin. This antidiabetic class is becoming more important among diabetic patients with CKD, due to their excellent tolerability profile [ — ].

Linagliptin has no renal excretion and therefore does not require adjustment for renal function. Until recently, the arsenal of noninsulin antidiabetic agents was not safe to be used in diabetic patients with CKD, and insulin therapy was started early, causing psychological distress to patients and families.

Nowadays, there are new noninsulin agents, DPP-4 inhibitors in particular, which present a low risk of hypoglycemia and can be used in patients with DM2 with CKD. However, further studies are required to confirm the safety of these new agents in this population.

Table 2 summarizes the recommendations for the use of noninsulin antidiabetic agents for noninsulin patients based on international guidelines [ 70 , , ]. The kidney plays an important role in clearing insulin from the systemic circulation and two distinct pathways have been described; one involves glomerular filtration and subsequent insulin absorption by proximal tubular cells through endocytosis; and the other is related to insulin diffusion through peritubular capillaries and their connection to the contraluminal tubular membrane, especially from the distal half of the nephron.

Therefore, insulin is transported by lysosomes and metabolized to amino acids that are released by diffusion in peritubular vessels, and final degradation products are then reabsorbed [ — ].

Endogenous insulin has a mean plasma half-life of only 6 min and it is almost cleared from the circulation within 10—15 min Fig. Except for the portion of insulin bound to its receptors on the target cells, the remainder is degraded mainly in the liver, to a lesser extent in kidney and muscle and slightly in most other tissues.

In contrast, exogenous insulin does not undergo the first-pass effect in the liver, the kidney plays an important role in the metabolism and clearance of circulating insulin in patients with renal failure Fig.

As a consequence, with the progression of CKD, insulin clearance decreases, thus requiring a dose reduction in order to avoid hypoglycemia [ , ]. Adapted from Iglesias and Díez [ ]. Schematic presentation of the clearance of insulin. a endogenous insulin and b exogenous insulin.

The pharmacokinetics of commercially available insulin in diabetic patients with reduced glomerular filtration rate has been evaluated for small number of studies.

Insulins are classified according to their action profile Table 3. Thus, the first exogenous insulins developed to control blood sugar, NPH Neutral Protamine Hagedorn and Regular insulin are labeled as having an intermediate- and rapid-acting profile, respectively.

One has a peak activity 4—7 h after subcutaneous injection, while the other one is used before meals in order to reduce the peak of hyperglycemia after the ingestion of carbohydrates.

However, its onset of action is between 30 min and 1 h and it must be applied around 30—45 min before the meal. The insulin analogs, produced by recombinant DNA technology, are classified as 1 short-acting lispro, aspart, and glulisine insulin , 2 long-acting glargine, detemir , or 3 ultra-long-acting degludec.

The association between the short-acting and the long- or ultra-long-acting insulin analogs enables physiological simulation of insulin secretion; this therapeutic association has been termed basal-bolus insulinization.

Due to its pharmacokinetic profile with a stable half-life and duration of action of about 24 h, glargine insulin can be prescribed once a day. To date, few studies have been published on the use of glargine insulin in patients with renal failure, and its use appears to be safe, with a reduction in HbA1c in a short period of time [ ].

Detemir insulin has an onset of drug action of 1 h, and its effect lasts 12—24 h. Thus, it is recommended that this drug be used in two daily doses, with intervals of about 12 h.

However, some patients could present different sensitivity along the day, and for this subgroup of patients a single-a-day dose may be enough to maintaining adequate glycemic control in the postprandial period [ , ]. A recent study [ ] demonstrated the need for dose reduction, for both glargine and detemir insulin, in patients with renal function impairment.

In this case, the dose of glargine and detemir insulin was Degludec insulin, with an ultra-long-action profile, has recently been approved to be commercialized, and only one study in patients with different stages of renal failure and terminal CKD has been published, showing no statistical significant differences in absorption or release profiles when compared to individuals with normal renal function.

Thus, degludec insulin does not require dose adjustments due to the loss of kidney function [ ]. As shown on Table 3 , the insulin analogs lispro, aspart, and glulisine have short durations and very similar pharmacokinetic profiles [ ].

Because lispro insulin was the first analog investigated, there are a number of studies in patients with CKD [ — ] showing it has a beneficial effect in reducing glomerular hyperfiltration and renal effects of hyperglycemia triggered by meals; these effects are possibly related to an antagonistic effect on insulin-like growth factor-1 [ ].

Furthermore, the use of lispro insulin was associated with improved glycemic control and quality of life in patients on hemodialysis by end-stage diabetic renal disease [ , ]. The glulisine and aspart insulin also had their safety and efficacy demonstrated in controlling postprandial hyperglycemia in patients with DM2 and severe renal failure [ ].

No change in the pharmacokinetic of these drugs was observed [ ]. Regardless of insulin being considered the best choice for glycemic control in patients with renal impairment, its prescription must be based on some guidelines, such as: 1 individualization of the therapy; 2 frequent reassessment of prescription or adjustment of doses for the glomerular filtration rate; 3 basal-bolus insulin regimens, prescribing intermediate- or long-acting profile insulin, as basal insulin, to keep the levels of blood glucose stable on post-absorptive period, associated with short-acting profile insulin to promote adequate carbohydrates metabolism and control of postprandial glycaemia; and 4 blood glucose monitoring and frequent adjustment of insulin therapy based on individual response [ ].

Few studies have reported specific information on the differences in action profiles, half-life, metabolism, and clearance of different insulin types available that are adjusted for the different stages of CKD; such studies would allow the prescription of more effective therapeutic regimens, minimizing risk of hypoglycemia, which is potentially more harmful in this population.

Therefore, the treatment should be individualized based on factors such as the presence of complications, associated diseases, disease management ability, stage and duration of CKD, and previous glycemic control [ — ].

In addition, there should be participation of a multidisciplinary team consisting of nephrologists, endocrinologists, nutritionists, and nurses. This approach has proved to be an effective strategy in achieving individual glycemic optimal values, reducing the rate of progression of kidney disease and other complications associated with DM2, and improving the quality of life of patients with DKD.

The relationship between DM and DKD is more complicated than the predisposition of a diabetic patient to develop kidney disease and the negative impact on morbidity and mortality of patients with kidney disease and DM. Recently, the kidney has been recognized as being directly involved in the pathogenesis of DM because of its ability to regulate glucose reabsorption as well as to determine insulin half-life and resistance.

In addition, it is now clear that glomerular filtration provides a safe and efficacious target for many hypoglycemic drugs. Thus, understanding the renal physiology and pathophysiology of DKD has become essential to all specialties treating diabetic patients.

American Diabetes Association. Standards of care in diabetes Diabetes Care. Article Google Scholar. DeFronzo Ralph. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Article CAS PubMed PubMed Central Google Scholar.

Porte D. Central regulation of energy homeostasis. Article CAS Google Scholar. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DC. Central nervous system control of food intake. CAS PubMed Google Scholar.

Plum L, Belgardt BF, Bruning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest. Bonadonna RC, Groop L, Kraemer N, Ferrannini E, Del Prato S, DeFronzo RA.

Obesity and insulin resistance in humans: a dose-response study. Article CAS PubMed Google Scholar. Shulman GI. Cellular mechanisms of insulin resistance. Parente EB, Pereira PHGR, Nunes VS, Lottenberg AMP, Lima CSLM, Rochitte CE, et al. The effects of high-fat or high-carbohydrate diet on intramyocellular lipids.

J Food Nutr Disord. Google Scholar. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol.

CAS Google Scholar. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man.

Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. Druker DJ.

Enhancing incretin action for the treatment of type 2 diabetes. Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol. Sivertsen J, Rosenmeier J, Holst JJ, Vilsbøll T. The effect of glucagon-like peptide 1 on cardiovascular risk.

Nat Rev Cardiol. Bergman H, Drury DR. The relationship of kidney function to the glucose utilization of the extra abdominal tissues. Am J Physiol. Meriel P, Galinier F, Suc J, et al. Le metabolisme duRein humaian. Rev Franc Etudes Clin Biol.

Nieth H, Schollmeyer P. Substrate utilization of the human kidney. Björkman O, Felig P. Role of the kidney in the metabolism of fructose in h fasted humans. Article PubMed Google Scholar. Aber G, Morris L, Housley E. Gluconeogenesis by the human kidney. Meyer C, Dostou J, Nadkarni V, Gerich J.

Effects of physiological hyperinsulinemia on systemic, renal and hepatic substrate metabolism. Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal glucose metabolism in humans. Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J.

Uptake and release of glucose by the human kidney: postabsorptive rates and responses to epinephrine. Stumvoll M, Meyer C, Kreider M, Perriello G, Gerich J. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans.

Schoolwerth A, Smith B, Culpepper R. Renal gluconeogenesis. Miner Electrolyte Metab. Wirthensohn G, Guder W. Renal substrate metabolism. Physiol Rev. Meyer C, Gerich JE. Role of the kidney in hyperglycemia in type 2 diabetes.

Curr Diab Rep. Abe M, Kalantar-Zadeh K. Hemodialysis induced hypoglycemia and glucose disarrays. Nat Rev Nephrol. Renal Data System. Incidence, prevalence, patient characteristics and treatment modalities.

National Institutes of Health, National Institute of Diabetes and Kidney Diseases. In: USRDS Annual data report. Bethesda; UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes: UKPDS Koenig RJ, Peterson CM, Jones RL, et al.

Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med. Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab.

The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, International Diabetes Federation. Consensus statement on the worldwide standardization of the HbA1c measurement.

Kilpatrick ES, Rigby AS, Atkin SL. Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin Chem. Miller WG, Myers GL, Ashwood ER, Killeen AA, Wang E, Ehlers GW, et al.

State of the art in trueness and interlaboratory harmonization for ten analytes in general clinical chemistry. Arch Pathol Lab Med. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes.

Arch Intern Med. Pimazoni-Netto A, Rodbard D, Zanella MT. Rapid improvement of glycemic control in type 2 diabetes using weekly intensive multifactorial interventions: structured glucose monitoring, patient education, and adjustment of therapy—a randomized controlled trial.

Diabetes Technol Ther. doi: Article PubMed PubMed Central Google Scholar. Nathan D, Davidson MB, Defronzo RA, Heine RJ, Henry RR, Pratley R, American Diabetes Association, et al.

Impaired fasting glucose and impaired glucose tolerance: implications for care. Lenters-Westra E, Schindhelm RK, Bilo HJ, et al. Haemoglobin A1c: historical overview and current concepts. Diabetes Res Clin Pract.

Chen HS, Wu TE, Lin HD, Jap TS, Hsiao LC, Lee SH, et al. Hemoglobin A 1c and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4. Am J Kidney Dis. Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE.

The national glycohemoglobin standardization program: a 5-year progress report. Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A 1c in the management of diabetes. J Diabetes.

Uzu T, Hatta T, Deji N, Izumiya T, Ueda H, Miyazawa I, et al. Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A 1c. Ther Apher Dial. Speeckaert M, Biesen WV, Delanghe J, Slingerland R, Wiecek A, Heaf J, The European Renal Best Practice Guideline Development Group on Diabetes in Advanced CKD, et al.

Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant. Beverage intake, diabetes, and glucose control of adults in America. Ann Epidemiol. Okada T, Nakao T, Matsumoto H, Yamanaka T, Nagaoka Y, Tamekuni T.

Influence of age and nutritional status on glycated albumin values in hemodialysis patients. Intern Med. Cohen RM, Holmes YR, Chenier TC, Joiner CH.

Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Skip directly to site content Skip directly to search. Español Other Languages. Diabetes and Chronic Kidney Disease Español Spanish Print. Minus Related Pages. Kidney Facts. Kidney diseases are the 9th leading cause of death in the United States.

Every 24 hours, people with diabetes begin treatment for kidney failure. How Diabetes Causes Kidney Disease Each kidney is made up of millions of tiny filters called nephrons.

Tips To Keep Your Kidneys Healthy You can help keep your kidneys healthy by managing your blood sugar, blood pressure, and cholesterol levels. Physical activity can help prevent kidney disease. Prediabetes and Kidney Disease If you have prediabetes, taking action to prevent type 2 diabetes is an important step in preventing kidney disease.

Get Tested for Chronic Kidney Disease Take Care of Your Kidneys Manage High Blood Pressure Living With Diabetes CDC Diabetes on Facebook CDCDiabetes on Twitter. Last Reviewed: December 30, Source: Centers for Disease Control and Prevention. Facebook Twitter LinkedIn Syndicate.

home Diabetes Home. To receive updates about diabetes topics, enter your email address: Email Address. What's this.

Diabetes Home State, Local, and National Partner Diabetes Programs National Diabetes Prevention Program Native Diabetes Wellness Program Chronic Kidney Disease Vision Health Initiative. Links with this icon indicate that you are leaving the CDC website.

The kidneys work hard to make up for the failing capillaries, so kidney disease produces no symptoms until almost all function is gone. Also, the symptoms of kidney disease are not specific. The first symptom of kidney disease is often fluid buildup. Other symptoms of kidney disease include loss of sleep, poor appetite, upset stomach, weakness, and difficulty concentrating.

It is vital to see a doctor regularly. The doctor can check blood pressure, urine for protein , blood for waste products , and organs for other complications of diabetes. Diabetes-related kidney disease can be prevented by keeping blood glucose in your target range. Research has shown that tight blood glucose management reduces the risk of microalbuminuria by one third.

In people who already had microalbuminuria, the risk of progressing to macroalbuminuria was cut in half. Other studies have suggested that tight management can reverse microalbuminuria. Important treatments for kidney disease are management of blood glucose and blood pressure.

Blood pressure has a dramatic effect on the rate at which the disease progresses. Even a mild rise in blood pressure can quickly make kidney disease worsen. Four ways to lower your blood pressure are:.

In addition to these steps and your diabetes medication, certain medications lower blood pressure. There are several kinds of blood pressure drugs. Work with your health care team about other medications that may be helpful for you to lower your risk of kidney disease.

You can plan a kidney-friendly meal by eating a balanced diet with a variety of whole, minimally processed foods and by following these general meal planning tips:. Talk to your health care provider about limiting fluid intake and to your registered dietician nutritionist RDN about other nutrition considerations.

You may need to limit certain nutrients like sodium, potassium, and phosphorus in your eating plan. Your nutrition care plan might change over time depending on the status of your condition. Your RDN or health care provider will tell you if changes are needed based on your blood test results.

Once kidneys fail, dialysis is necessary. The person must choose whether to continue with dialysis or to get a kidney transplant. This choice should be made as a team effort. The team should include your doctor, diabetes educator, RDN, a nephrologist kidney doctor , a kidney transplant surgeon, a social worker, and a psychologist.

If you or someone in your family has diabetes, high blood pressure, or a history of kidney disease, you could be at risk for serious complications. There are many ways to help delay kidney failure, especially when chronic kidney disease is diagnosed in the earlier stages.

A kidney transplant is the best possible treatment option for patients with kidney failure. If you aren't eligible for a kidney transplant, other options are available. Breadcrumb Home About Diabetes Diabetes Complications Chronic Kidney Disease Nephropathy. Start My Kidney Journey.

How does diabetes cause kidney disease? Who gets kidney disease? What are the symptoms? How can I prevent it? Treatments for Kidney Disease. Self-Care Important treatments for kidney disease are management of blood glucose and blood pressure.

Four ways to lower your blood pressure are: Losing weight, if needed, or maintaining a healthy weight Eating a kidney-friendly eating plan see Kidney Friendly Eating Plan section below Avoiding alcohol and tobacco Getting regular physical activity Medication In addition to these steps and your diabetes medication, certain medications lower blood pressure.

You can help keep your kidneys healthy by managing your blood sugar, blood pressure, and cholesterol levels. This is also very important for your heart and blood vessels—high blood sugar, blood pressure, and cholesterol levels are all risk factors for heart disease and stroke.

If you have prediabetes, taking action to prevent type 2 diabetes is an important step in preventing kidney disease. You can do that by eating healthier and getting minutes of physical activity each week. Find a program in your community or online. Skip directly to site content Skip directly to search.

Español Other Languages. Diabetes and Chronic Kidney Disease Español Spanish Print. Minus Related Pages. Kidney Facts. Kidney diseases are the 9th leading cause of death in the United States. Every 24 hours, people with diabetes begin treatment for kidney failure.

How Diabetes Causes Kidney Disease Each kidney is made up of millions of tiny filters called nephrons. Tips To Keep Your Kidneys Healthy You can help keep your kidneys healthy by managing your blood sugar, blood pressure, and cholesterol levels.

Physical activity can help prevent kidney disease. Prediabetes and Kidney Disease If you have prediabetes, taking action to prevent type 2 diabetes is an important step in preventing kidney disease.

Get Tested for Chronic Kidney Disease Take Care of Your Kidneys Manage High Blood Pressure Living With Diabetes CDC Diabetes on Facebook CDCDiabetes on Twitter.

Last Reviewed: December 30, Source: Centers for Disease Control and Prevention. Facebook Twitter LinkedIn Syndicate.

Similarly, the serum creatinine, serum potassium, and blood pressure, plus the patient's volume status, should generally be ascertained within a few weeks of commencing a sodium-glucose cotransporter 2 SGLT2 inhibitor. See "Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Hypotension'.

Both RAS inhibition and SGLT2 inhibitors may increase the risk of symptomatic hypotension, and other antihypertensive therapies should be withdrawn first if possible before considering cessation of these evidence-based therapies.

Similarly, SGLT2 inhibitors may cause volume depletion, and withdrawal or reduction of thiazide or loop diuretics should be attempted before discontinuing the SGLT2 inhibitor.

See "Definition and staging of chronic kidney disease in adults", section on 'Referral to a specialist'. PROGNOSIS — A substantial proportion of people with diabetic kidney disease DKD will have progressive loss of kidney function and will develop end-stage kidney disease ESKD.

The strongest risk factor for risk of progression is the presence of increased albuminuria, while people with reduced estimated glomerular filtration rate eGFR or anemia are also at increased risk.

With available protective therapies, a dramatic stabilization of kidney function is likely to be achievable. See "Diabetic kidney disease: Manifestations, evaluation, and diagnosis", section on 'Natural history'. Of note, people with DKD are at particularly high risk of cardiovascular events, and most have a higher risk of death mostly cardiovascular than developing kidney failure.

Cardiovascular protective therapies are therefore also critical. See "Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Reducing the risk of macrovascular disease'.

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. See "Society guideline links: Glomerular disease in adults" and "Society guideline links: Chronic kidney disease in adults" and "Society guideline links: Diabetic kidney disease".

These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed.

These articles are written at the 10 th to 12 th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon. Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients.

You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword s of interest. The evidence supporting our recommendation is presented separately. See "Goal blood pressure in adults with hypertension", section on 'Patients with chronic kidney disease' and "Goal blood pressure in adults with hypertension", section on 'Patients with diabetes mellitus' and 'Blood pressure control' above.

However, glycemic targets in type 1 diabetes have not been well studied in patients with advanced chronic kidney disease CKD.

The approach to target an A1C of 7 percent or less, if tolerated is similar in patients with type 2 diabetes, although fewer supportive data are available than for type 1 diabetes. The evidence for these approaches is presented elsewhere. See "Glycemic control and vascular complications in type 1 diabetes mellitus" and "Glycemic control and vascular complications in type 2 diabetes mellitus" and 'Glycemic control' above.

See 'Other' above. However, while these drugs are more beneficial than other antihypertensive agents in patients with albuminuric DKD, they do not have clear advantages over calcium channel blockers or diuretics among those without albuminuria.

See 'Severely increased albuminuria: Treat with angiotensin inhibition' above. We also suggest use of an SGLT2 inhibitor in patients with DKD who have lower levels of urine albumin excretion Grade 2B.

The SGLT2 inhibitor is typically added to the patient's existing glucose-lowering regimen since these drugs have weak glucose-lowering effects in patients with reduced kidney function. See 'Type 2 diabetes: Treat with additional kidney-protective therapy' above.

SGLT2 inhibitors increase the risk of genital infections by two- to fourfold primarily vulvovaginal candidiasis and have been associated with Fournier's gangrene in rare cases. SGLT2 inhibitors are not appropriate for use in patients with type 1 diabetes and kidney disease.

See 'Monitoring during therapy' above. Why UpToDate? Product Editorial Subscription Options Subscribe Sign in. Learn how UpToDate can help you. Select the option that best describes you. View Topic. Font Size Small Normal Large. Treatment of diabetic kidney disease.

Formulary drug information for this topic. No drug references linked in this topic. Find in topic Formulary Print Share. View in. Language Chinese English.

Authors: Vlado Perkovic, MBBS, PhD Sunil V Badve, MD, PhD George L Bakris, MD Section Editors: Richard J Glassock, MD, MACP David M Nathan, MD Deputy Editor: John P Forman, MD, MSc Contributor Disclosures. All topics are updated as new evidence becomes available and our peer review process is complete.

Literature review current through: Jan This topic last updated: Jul 17, aspx Accessed on March 05, Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

N Engl J Med ; Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.

Cochrane Database Syst Rev ; :CD Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial.

The Diabetes Control and Complications DCCT Research Group. Kidney Int ; Hemmingsen B, Lund SS, Gluud C, et al.

Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Amod A, Buse JB, McGuire DK, et al. Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis DEVOTE Diabetes Ther ; Davis TM, Brown SG, Jacobs IG, et al.

Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab ; Alsahli M, Gerich JE.

Hypoglycemia, chronic kidney disease, and diabetes mellitus. Mayo Clin Proc ; Flynn C, Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis.

Nat Rev Nephrol ; Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. Hebert LA, Bain RP, Verme D, et al. Remission of nephrotic range proteinuria in type I diabetes.

Collaborative Study Group. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med ; Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.

Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol ; Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.

Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus the ADVANCE trial : a randomised controlled trial.

Lancet ; Kaplan NM. Vascular outcome in type 2 diabetes: an ADVANCE? Bakris GL, Berkwits M. Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes.

Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk the ONTARGET study : a multicentre, randomised, double-blind, controlled trial.

Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. Mann JF, Anderson C, Gao P, et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial.

J Hypertens ; Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. American Diabetes Association. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes Diabetes Care ; S Palmer SC, Tendal B, Mustafa RA, et al.

Sodium-glucose cotransporter protein-2 SGLT-2 inhibitors and glucagon-like peptide-1 GLP-1 receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ ; m Dekkers CCJ, Wheeler DC, Sjöström CD, et al.

Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. Nephrol Dial Transplant ; Salah HM, Al'Aref SJ, Khan MS, et al.

Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.

Am Heart J ; Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. Dave CV, Kim SC, Goldfine AB, et al.

Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Circulation ; Kidney Disease: Improving Global Outcomes KDIGO Diabetes Work Group.

KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int ; S1. de Boer IH, Khunti K, Sadusky T, et al.

Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association ADA and Kidney Disease: Improving Global Outcomes KDIGO. Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.

Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI.

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Lancet Diabetes Endocrinol ; Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. Wanner C, Heerspink HJL, Zinman B, et al.

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. Bhatt DL, Szarek M, Pitt B, et al.

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. Bakris G, Oshima M, Mahaffey KW, et al. Clin J Am Soc Nephrol ; Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.

Dapagliflozin in Patients with Chronic Kidney Disease. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease.

Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium.

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Zinman B, Inzucchi SE, Lachin JM, et al. Cardiovasc Diabetol ; Zinman B, Wanner C, Lachin JM, et al.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study CANVAS --a randomized placebo-controlled trial.

Neal B, Perkovic V, Matthews DR, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal CANVAS-R : A randomized, placebo-controlled trial.

Diabetes Obes Metab ; Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.

Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Wiviott SD, Raz I, Bonaca MP, et al.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Bersoff-Matcha SJ, Chamberlain C, Cao C, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.

Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J ; Bakris GL, Agarwal R, Chan JC, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

JAMA ; Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. Agarwal R, Filippatos G, Pitt B, et al.

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.

Ito S, Kashihara N, Shikata K, et al. Esaxerenone CS in Patients with Type 2 Diabetes and Microalbuminuria ESAX-DN : Phase 3 Randomized Controlled Clinical Trial. Ito S, Shikata K, Nangaku M, et al. Efficacy and Safety of Esaxerenone CS for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

Ito S, Itoh H, Rakugi H, et al. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone CS and Eplerenone in Patients With Essential Hypertension ESAX-HTN Study.

Hypertension ; Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease AWARD-7 : a multicentre, open-label, randomised trial.

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Cornel JH, Bakris GL, Stevens SR, et al. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care ; Wexler DJ, de Boer IH, Ghosh A, et al.

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. Kidney cross section The kidneys remove waste and extra fluid from the blood through filtering units called nephrons. By Mayo Clinic Staff.

Show references Diabetic kidney disease. National Institute of Diabetes and Digestive and Kidney Diseases. Accessed May 24, Diabetic kidney disease adult. Mayo Clinic; Mottl AK, et al. Diabetic kidney disease: Manifestations, evaluation, and diagnosis. Diabetes and chronic kidney disease.

Centers for Disease Control and Prevention. Diabetic nephropathy. Merck Manual Professional Version. Goldman L, et al.

Diabetes mellitus. In: Goldman-Cecil Medicine. Elsevier; Elsevier Point of Care. Clinical Overview: Diabetic nephropathy.

De Boer IH, et al. Executive summary of the KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment. Kidney International. Office of Patient Education. Chronic kidney disease treatment options. Coping effectively: A guide for patients and their families.

National Kidney Foundation. Robertson RP. Pancreas and islet cell transplantation in diabetes mellitus. Accessed May 25, Ami T. Allscripts EPSi. Mayo Clinic. June 27, Castro MR expert opinion.

June 8, Chebib FT expert opinion. Mayo Clinic Press Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press. Mayo Clinic on Incontinence - Mayo Clinic Press Mayo Clinic on Incontinence The Essential Diabetes Book - Mayo Clinic Press The Essential Diabetes Book Mayo Clinic on Hearing and Balance - Mayo Clinic Press Mayo Clinic on Hearing and Balance FREE Mayo Clinic Diet Assessment - Mayo Clinic Press FREE Mayo Clinic Diet Assessment Mayo Clinic Health Letter - FREE book - Mayo Clinic Press Mayo Clinic Health Letter - FREE book.

Show the heart some love! Give Today. Help us advance cardiovascular medicine. Find a doctor. Explore careers. Sign up for free e-newsletters.

About Mayo Clinic. About this Site. Contact Us. Health Information Policy. Media Requests. News Network. Price Transparency. Medical Professionals. Clinical Trials. Mayo Clinic Alumni Association. Refer a Patient. Executive Health Program.

International Business Collaborations. Supplier Information. Admissions Requirements. Degree Programs. Research Faculty.